GFAP and Alzheimer disease: To address this knowledge gap, this study aims to first replicate findings in the field demonstrating the ability of blood‐based biomarkers relevant to AD (GFAP, NfL, Aβ42, and p‐tau231) to predict cross‐sectional and longitudinal neuropsychological and neuroimaging outcomes reflective of cognitive decline and neurodegeneration.